Daniela Semedo, PhD,  —

X-Chem Pharmaceuticals and Vertex Pharmaceuticals will jointly develop small molecules targeting cystic fibrosis (CF) and other severe genetic diseases. Under the collaboration announced May 16, X-Chem will apply its proprietary DEX libraries — which holds more than 120 billion small compounds — to discover new drug candidates against targets involved in CF…

Dalton and Arch Biopartners are partnering to manufacture AB569 for clinical trials involving cystic fibrosis (CF) patients with chronic, antibiotic-resistant bacterial lung infections. Under the agreement, the two will divide manufacturing tasks, including formulating the compound, putting it in containers safely, and doing quality-control testing. The drug will be…

Savara has received U.S. and Canadian patents for its AeroVanc powdered, inhaled formulation of the antibiotic vancomycin hydrochloride, which combats treatment-resistant lung infections in cystic fibrosis (CF) patients. AeroVanc addresses the growing challenge of the methicillin-resistant Staphylococcus aureus (MRSA) bacteria, Savara said in a press release. The patents from the United States Patent and Trademark…

Fifteen non-profit groups in seven countries will receive Cystic Fibrosis Circle of Care project grants totaling nearly $1 million this year, the program’s sponsor, Vertex Pharmaceuticals, announced. The grants, now in their third year, go to medical, academic, patient, and community organizations serving the cystic fibrosis (CF) community. Since the program started in…

A new test able to screen for the risk for inherited conditions such as cystic fibrosis (CF) will be jointly commercialized by SYNLAB and Counsyl, two companies dedicated to the development of genetic screening tests. Under a new agreement signed by the two companies, SYNLAB will offer Counsyl’s…

The United States and Canada have given Laurent Pharmaceuticals a green light for a Phase 2 clinical trial of LAU-7b as a treatment for cystic fibrosis (CF) in adults. The Phase 2 door was opened when the U.S. Food and Drug Administration (FDA) and Health Canada approved the company’s investigational new drug (IND) application…

Arch Biopartners is on the verge of its first clinical trial of AB569, an inhalation treatment for antibiotic-resistant bacteria that infect the lungs of those with cystic fibrosis (CF) and other pulmonary conditions. The Phase 1 clinical trial, to be conducted at the Cincinnati Veterans Affairs Medical Center (CVAMC),…

Enterprise Therapeutics has received a £95,000 grant from Britain’s Cystic Fibrosis Trust to develop innovative treatments for cystic fibrosis (CF). The money, equivalent to $118,000, will support the development of CF therapies based on Enterprise Therapeutics’ bronchosphere technology platform. Cystic fibrosis blocks airway passages. The condition stems from faulty airway-surface…

AbbVie is accepting applications for its 2017 AbbVie CF Scholarship program that helps to support outstanding young adults with cystic fibrosis (CF) as they pursue higher education. A total of 40 scholarships, each worth $3,000, are available for the current 2017–18 academic year. Awards based on established criteria that…

Corbus Pharmaceuticals recently reported that its Phase 2 clinical trial examining multiple doses of anabasum (formerly known as JBT-101 or Resunab) compared to placebo in patients with cystic fibrosis (CF) achieved the trial’s primary endpoint demonstrating an acceptable safety and tolerability profile at all doses, with no serious or severe adverse…